Paridiprubart

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Paridiprubart
www.ebi.ac.uk

  • eb 05
  • EB-05
  • eb05
  • EB05
  • Immunoglobulin G1 [326-serine,329-phenylalanine,de-448-lysine], anti-(human Toll-like receptor 4) (human-Mus musculus monoclonal EB05 γ1-chain), disulfide with human-Mus musculus monoclonal EB05 κ-chain, dimer
  • immunoglobulin g1 326 serine 329 phenylalanine de 448 lysine anti human toll like receptor 4 human mus musculus monoclonal eb05 γ1 chain disulfide with human mus musculus monoclonal eb05 κ chain dimer
  • ni 0101
  • Ni-0101
  • NI-0101
  • paridiprubart
  • Paridiprubart
  • paridiprubart [INN]
  • PARIDIPRUBART [USAN]
  • paridiprubart inn
  • paridiprubart usan

CAS registry numbers
  • 2641646-59-3
ChEMBL ID
CHEMBL5095366
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • 4LH8QAS0LR

First in class
No
Orphan designation
No

Pharmacology name
paridiprubart
Type
Antibody
Drug name stem
-bart

Mechanisms of action

  • Action
    Binding
    Action type
    Binding
    Target
    TLR4
    Gene symbol
    TLR4
    Protein identifier
    O00206
    Median affinity
    9.86
    Affinity units
    pKd

  • Condition
    Cytokine Release Syndrome
    Highest recorded phase
    1
    Subject identifier
    D000080424
  • Condition
    Arthritis, Rheumatoid
    Highest recorded phase
    2
    Condition identifier
    EFO:0000685
    Subject identifier
    D001172
  • Condition
    Severe Acute Respiratory Syndrome
    Highest recorded phase
    2
    Condition identifier
    EFO:0000694
    Subject identifier
    D045169
  • Condition
    Respiratory Distress Syndrome
    Highest recorded phase
    1
    Condition identifier
    EFO:1000637
    Subject identifier
    D012128
  • Condition
    Severe Acute Respiratory Syndrome
    Highest recorded phase
    2
    Condition identifier
    MONDO:0100096
    Subject identifier
    D045169
  • Condition
    Inflammation
    Highest recorded phase
    1
    Condition identifier
    MP:0001845
    Subject identifier
    D007249

  • Condition identifier
    EFO_0000685
    Highest recorded phase
    2
  • Condition identifier
    EFO_0000694
  • Condition identifier
    EFO_1000637
  • Condition identifier
    MONDO_0005147
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0006502
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0008383
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0100096
  • Condition identifier
    MONDO_0100096
    Highest recorded phase
    2
  • Condition identifier
    MP_0001845

Prodrug
No
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    QVQLQESGPGLVKPSDTLSLTCAVSGYSITGGYSWHWIRQPPGKGLEWMGYIHYSGYTDFNPSLKTRITISRDTSKNQFSLKLSSVTAVDTAVYYCARKDPSDAFPYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSSKAFPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Light chain
    Type
    Protein
    Sequence
    EIVLTQSPDFQSVTPKEKVTITCRASQSISDHLHWYQQKPDQSPKLLIKYASHAISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQGHSFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGSSPVTKSFNRGEC
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 145-201 $ 145''-201'' $ 221-214' $ 221''-214''' $ 227-227'' $ 230-230'' $ 262-322 $ 262''-322'' $ 368-426 $ 368''-426''
  • Component
    Glycosylation sites (N)
    Sequence
    298 $ 298''

Related records

Trials (3)

In development for (6)

Targets (1)